Perinatal Stem Cells

Anthony Atala, MD, is the G. Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. Fifteen applications of technologies developed in Dr. Atala's laboratory have been used clinically. He is Editor of 25 books and 3 journals. Dr. Atala has published over 800 journal articles and has received over 250 national and international patents. Dr. Atala was elected to the Institute of Medicine of the National Academies of Sciences, to the National Academy of Inventors as a Charter Fellow, and to the American Institute for Medical and Biological Engineering. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the National Institutes of Health Bioengineering Consortium, and the National Cancer Institute’s Advisory Board. He is a founding member of the Tissue Engineering Society, Regenerative Medicine Foundation, Regenerative Medicine Manufacturing Innovation Consortium, Regenerative Medicine Development Organization, and Regenerative Medicine Manufacturing Society.

• Section I. Amniotic Fluid-Derived Stem Cells1. In utero therapy for congenital disorders using amniotic fluid stem cells2. The Amniotic Fluid Stem Cell Secretome: at the Heart of Regeneration3. Transplantation of Amniotic Fluid-Derived Neural Stem Cells4. Stroke therapy: the potential of amniotic fluid-derived stem cells 5. Vascular formation by human perinatal stem cells6. Amniotic Fluid Stem Cells for Kidney RegenerationSection II. Placental and Placental Membrane-Derived Stem Cells7. Placental mesenchymal stem cells for cellular cardiomyoplasty8. Heterogeneous functions of perinatal mesenchymal stromal cells require a preselection before their banking for clinical use 9. Defining the fetal stem cell niche in the human placenta10. Banking placental tissue hematopoietic stem cells and mesenchymal stem cells for clinical use11. Immuno-modulatory mechanisms of placental stem cells12. Amnion Membrane Allograft for Regenerative Medicine13. Perinatal cells and biomaterials for wound healing14. Placental Stem Cells15. Therapeutic Effect of Extracellular Vesicles Derived from Adult/Perinatal Human Mesenchymal Stem CellsSection III. Umbilical Cord-Derived Cells16. Ex-vivo Expansion of Cord Blood Stem Cells17. Cord Blood Transplantation: Therapeutic Use of Perinatal Stem Cells 18. Autologous Human Cord Blood as a Treatment for Traumatic Brain Injury in Children19. Phenotypic and Functional Characterization Perinatal Stem Cells Isolated from Umbilical Cord Tissue20. Mesenchymal stromal cells from Wharton’s jelly (WJ-MSCs): coupling their hidden differentiative program with their frank immunomodulatory phenotype21. Regeneration of ischemic cardiovascular damage using Jelly Wharton as an unlimited source of therapeutic stem cells22. Phenotype with Focused Paracrine Fractions: Effecting Future Phenotype with Focused Paracrine FractionsSection IV. Clinical and Industry Perspective23. Clinical Translation of Perinatal Stem Cell Therapy 24. Current Clinical Trials utilizing Perinatal Stem Cells – A Review 25. Review Of Processing Technology and Techniques for Perinatal Stem Cells Banking And Clinical Applications26. Clinical Development And Commercialization Of Placenta-Derived Cell Therapy 27. How the patent landscape has changed28. The Need for Better Assays to Predict the Effectiveness of Tissue Stem Cell Treatments